|
|
|
Insider
Information: |
Moriarty John B |
Relationship: |
|
City: |
Cheshire |
State: |
CT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
74,537 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$13,603,003 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
74,537 |
|
|
Total
Value |
$13,603,003 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alexion Pharmaceuticals Inc |
ALXN |
EVP & General Counsel |
2018-02-08 |
74,537 |
2012-12-10 |
0 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
EVP, General Counsel |
2020-07-02 |
0 |
2018-03-29 |
0 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-08-05 |
4 |
S |
$198.12 |
$1,986,377 |
D/D |
(10,010) |
32,418 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2014-12-11 |
4 |
S |
$195.53 |
$698,042 |
D/D |
(3,570) |
20,962 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-08-07 |
4 |
S |
$190.01 |
$25,651 |
D/D |
(135) |
42,283 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP & General Counsel |
|
2014-10-27 |
4 |
AS |
$189.49 |
$1,894,937 |
D/D |
(10,000) |
24,532 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-12-11 |
4 |
S |
$182.65 |
$172,311 |
D/D |
(943) |
41,340 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-03-02 |
4 |
S |
$180.34 |
$50,495 |
D/D |
(280) |
33,342 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP & General Counsel |
|
2014-10-06 |
4 |
AS |
$179.00 |
$1,790,000 |
D/D |
(10,000) |
24,532 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-02-09 |
4 |
S |
$174.16 |
$253,403 |
D/D |
(1,455) |
28,267 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-02-10 |
4 |
S |
$171.15 |
$255,014 |
D/D |
(1,490) |
26,777 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2015-06-11 |
4 |
S |
$170.00 |
$155,380 |
D/D |
(914) |
32,428 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP & General Counsel |
|
2014-02-07 |
4 |
S |
$155.55 |
$161,198 |
D/D |
(1,036) |
22,232 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2016-02-05 |
4 |
S |
$141.75 |
$282,447 |
D/D |
(1,969) |
51,134 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2016-02-29 |
4 |
S |
$138.91 |
$166,833 |
D/D |
(1,201) |
52,278 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2016-02-08 |
4 |
S |
$138.02 |
$363,577 |
D/D |
(2,633) |
48,501 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2016-08-08 |
4 |
S |
$137.14 |
$18,514 |
D/D |
(135) |
51,225 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2016-06-13 |
4 |
S |
$135.72 |
$124,591 |
D/D |
(918) |
51,360 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2017-03-01 |
4 |
S |
$132.50 |
$37,365 |
D/D |
(282) |
44,672 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2017-02-28 |
4 |
S |
$131.71 |
$119,856 |
D/D |
(910) |
44,954 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2017-02-27 |
4 |
S |
$131.20 |
$80,294 |
D/D |
(612) |
45,864 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2017-02-09 |
4 |
S |
$126.84 |
$21,182 |
D/D |
(167) |
46,476 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2016-12-12 |
4 |
S |
$118.61 |
$123,829 |
D/D |
(1,044) |
50,181 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2018-02-05 |
4 |
S |
$117.26 |
$147,865 |
D/D |
(1,261) |
49,911 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
|
2018-02-08 |
4 |
S |
$115.70 |
$389,099 |
D/D |
(3,363) |
74,537 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP & General Counsel |
|
2014-10-06 |
4 |
OE |
$95.65 |
$956,500 |
D/D |
10,000 |
34,532 |
0 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
SVP & General Counsel |
|
2014-10-06 |
4/A |
OE |
$92.65 |
$926,500 |
D/D |
10,000 |
24,532 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|